{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:41:42Z","timestamp":1788871302267,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T00:00:00Z","timestamp":1580428800000},"content-version":"vor","delay-in-days":2617,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002736","name":"Covidien","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002736","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Endo Pharmaceuticals"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpsmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pain and Symptom Management"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.jpainsymman.2011.12.280","type":"journal-article","created":{"date-parts":[[2012,7,11]],"date-time":"2012-07-11T10:46:49Z","timestamp":1342003609000},"page":"852-865","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Safety and Tolerability of Once-Daily OROS\u00ae Hydromorphone Extended-Release in Opioid-Tolerant Adults With Moderate-to-Severe Chronic Cancer and Noncancer Pain: Pooled Analysis of 11 Clinical Studies"],"prefix":"10.1016","volume":"44","author":[{"given":"Srinivas R.","family":"Nalamachu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kutch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin E.","family":"Hale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpainsymman.2011.12.280_bib1","series-title":"Bonica's management of pain","first-page":"13","article-title":"Pain terms and taxonomies of pain","author":"Turk","year":"2010"},{"key":"10.1016\/j.jpainsymman.2011.12.280_bib2","series-title":"Health, United States, 2006, with chartbook on trends in the health of Americans","year":"2006"},{"key":"10.1016\/j.jpainsymman.2011.12.280_bib3","unstructured":"U.S. Census Bureau. Preliminary Annual Estimates of the Resident Population of the United States,\u00a0Regions, and Puerto Rico: April 1, 2000 to July 1, 2010 (NST-PEST2010-01). 2002 estimate. Available from http:\/\/www.census.gov\/popest\/research\/eval-estimates\/eval-es+2010.html. Accessed April 4, 2012."},{"key":"10.1016\/j.jpainsymman.2011.12.280_bib4","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/MJT.0b013e31818164f2","article-title":"The impact of pain on quality of life and the unmet needs of pain management: results from pain sufferers and physicians participating in an Internet survey","volume":"15","author":"McCarberg","year":"2008","journal-title":"Am J Ther"},{"key":"10.1016\/j.jpainsymman.2011.12.280_bib5","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jpainsymman.2009.06.002","article-title":"Establishing \u201cbest practices\u201d for opioid rotation: conclusions of an expert panel","volume":"38","author":"Fine","year":"2009","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.jpainsymman.2011.12.280_bib6","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1185\/03007990903120158","article-title":"Opioid switching and rotation in primary care: implementation and clinical utility","volume":"25","author":"Slatkin","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jpainsymman.2011.12.280_bib7","unstructured":"U.S. Department of Health and Human Services, U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee: Risk Evaluation and Mitigation Strategies (REMS) for Extended-Release and Long-Acting Opioid Analgesics, July 22-23, 2010, Adelphi, MD. Available from http:\/\/www.fda.gov\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/AnestheticAndLifeSupportDrugsAdvisoryCommittee\/ucm193298.htm. Accessed June 27,\u00a02011."},{"key":"10.1016\/j.jpainsymman.2011.12.280_bib8","first-page":"113","article-title":"Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain","volume":"10","author":"Chou","year":"2009","journal-title":"J\u00a0Pain"},{"key":"10.1016\/j.jpainsymman.2011.12.280_bib9","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1213\/00000539-200004000-00029","article-title":"Opioid substitution to improve the effectiveness of chronic noncancer pain control: a chart review","volume":"90","author":"Quang-Cantagrel","year":"2000","journal-title":"Anesth Analg"},{"key":"10.1016\/j.jpainsymman.2011.12.280_bib10","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0885-3924(02)00643-7","article-title":"A\u00a0systematic review of hydromorphone in acute and chronic pain","volume":"25","author":"Quigley","year":"2003","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.jpainsymman.2011.12.280_bib11","series-title":"Exalgo (hydromorphone HCl) extended-release tablets. [package insert]","year":"2010"},{"key":"10.1016\/j.jpainsymman.2011.12.280_bib12","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2165\/11536540-000000000-00000","article-title":"Implications of opioid analgesia for medically complicated patients","volume":"27","author":"Smith","year":"2010","journal-title":"Drugs Aging"},{"key":"10.1016\/j.jpainsymman.2011.12.280_bib13","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.pain.2004.09.019","article-title":"Opioids in chronic non-cancer pain: systematic review of efficacy and safety","volume":"112","author":"Kalso","year":"2004","journal-title":"Pain"},{"key":"10.1016\/j.jpainsymman.2011.12.280_bib14","doi-asserted-by":"crossref","first-page":"816","DOI":"10.4140\/TCP.n.2010.816","article-title":"Oral hydromorphone extended-release","volume":"25","author":"Guay","year":"2010","journal-title":"Consult Pharm"},{"key":"10.1016\/j.jpainsymman.2011.12.280_bib15","doi-asserted-by":"crossref","first-page":"351","DOI":"10.5055\/jom.2010.0032","article-title":"Steady-state pharmacokinetics of extended-release hydromorphone (OROS hydromorphone): a randomized study in healthy volunteers","volume":"6","author":"Moore","year":"2010","journal-title":"J\u00a0Opioid Manag"},{"key":"10.1016\/j.jpainsymman.2011.12.280_bib16","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1185\/03007995.2010.484723","article-title":"Once-daily OROS hydromorphone ER compared with placebo in opioid-tolerant patients with chronic low back pain","volume":"26","author":"Hale","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jpainsymman.2011.12.280_bib17","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1472-684X-7-17","article-title":"A\u00a0randomized, double-blind comparison of OROS hydromorphone and controlled-release morphine for the control of chronic cancer pain","volume":"7","author":"Hanna","year":"2008","journal-title":"BMC Palliat Care"},{"key":"10.1016\/j.jpainsymman.2011.12.280_bib18","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1472-684X-8-14","article-title":"An open-label, 1-year extension study of the long-term safety and efficacy of once-daily OROS hydromorphone in patients with chronic cancer pain","volume":"8","author":"Hanna","year":"2009","journal-title":"BMC Palliat Care"},{"key":"10.1016\/j.jpainsymman.2011.12.280_bib19","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/j.1533-2500.2009.00342.x","article-title":"A\u00a0randomized study to demonstrate noninferiority of once-daily OROS hydromorphone with twice-daily sustained-release oxycodone for moderate to severe chronic noncancer pain","volume":"10","author":"Binsfeld","year":"2010","journal-title":"Pain Pract"},{"key":"10.1016\/j.jpainsymman.2011.12.280_bib20","doi-asserted-by":"crossref","first-page":"97","DOI":"10.5055\/jom.2009.0011","article-title":"Long-term safety, tolerability, and efficacy of OROS hydromorphone in patients with chronic pain","volume":"5","author":"Wallace","year":"2009","journal-title":"J\u00a0Opioid Manag"},{"key":"10.1016\/j.jpainsymman.2011.12.280_bib21","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1185\/030079907X182040","article-title":"Efficacy and safety evaluation of once-daily OROS hydromorphone in patients with chronic low back pain: a pilot open-label study (DO-127)","volume":"23","author":"Wallace","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jpainsymman.2011.12.280_bib22","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1111\/j.1526-4637.2010.00956.x","article-title":"Open-label study on the long-term efficacy, safety, and impact on quality of life of OROS hydromorphone ER in patients with chronic low back pain","volume":"11","author":"Wallace","year":"2010","journal-title":"Pain Med"},{"key":"10.1016\/j.jpainsymman.2011.12.280_bib23","first-page":"343","article-title":"Conversion from standard opioid therapy to once-daily oral extended-release hydromorphone in patients with chronic cancer pain","volume":"36","author":"Wallace","year":"2008","journal-title":"J\u00a0Int Med Res"},{"key":"10.1016\/j.jpainsymman.2011.12.280_bib24","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1111\/j.1742-1241.2007.01500.x","article-title":"Once-daily OROS hydromorphone for the management of chronic nonmalignant pain: a dose-conversion and titration study","volume":"61","author":"Wallace","year":"2007","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jpainsymman.2011.12.280_bib25","article-title":"Sustained safety and efficacy of once-daily hydromorphone extended-release (OROS\u00ae hydromorphone ER) compared with twice-daily oxycodone controlled-release over 52 weeks in patients with moderate to severe chronic noncancer pain","author":"Richarz","year":"2012","journal-title":"Pain Pract"},{"key":"10.1016\/j.jpainsymman.2011.12.280_bib26","doi-asserted-by":"crossref","unstructured":"Vandenbossche J, Richarz U, Richards HM. A repeat-dose, steady-state pharmacokinetic evaluation of once-daily hydromorphone ER (OROS hydromorphone) in patients with chronic cancer or noncancer pain. Paper presented at the 30th Annual Scientific Meeting of the American Pain Society, May 19-21, 2011, Austin, TX.","DOI":"10.2147\/JPR.S33807"},{"key":"10.1016\/j.jpainsymman.2011.12.280_bib27","series-title":"Embeda (morphine sulfate and naltrexone hydrochloride) [package insert]","year":"2009"},{"key":"10.1016\/j.jpainsymman.2011.12.280_bib28","series-title":"OxyContin (oxycodone HCl controlled-release) tablets [package insert]","year":"2010"},{"key":"10.1016\/j.jpainsymman.2011.12.280_bib29","series-title":"Duragesic (fentanyl transdermal system) [package insert]","year":"2009"},{"key":"10.1016\/j.jpainsymman.2011.12.280_bib30","series-title":"Opana ER (oxymorphone hydrochloride) extended-release tablets [package insert]","year":"2008"},{"key":"10.1016\/j.jpainsymman.2011.12.280_bib31","article-title":"Results of a double-blind, placebo-conrolled, fixed-dose assessment of once-daily OROS\u00ae hydromorphone ER in patients with moderate to severe pain associated with chronic osteoarthritis","author":"Rauck","year":"2012","journal-title":"Pain Pract"},{"key":"10.1016\/j.jpainsymman.2011.12.280_bib32","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.clinthera.2007.05.016","article-title":"Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis","volume":"29","author":"Hale","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.jpainsymman.2011.12.280_bib33","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1533-2500.2008.00204.x","volume":"8","author":"Pergolizzi","year":"2008","journal-title":"Pain Pract"},{"key":"10.1016\/j.jpainsymman.2011.12.280_bib34","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S0009-9236(03)00152-8","article-title":"Side effects of opioids during short-term administration: effect of age, gender, and race","volume":"74","author":"Cepeda","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jpainsymman.2011.12.280_bib35","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/AJP.0b013e31815d3619","article-title":"Response to morphine in male and female patients: analgesia and adverse events","volume":"24","author":"Bijur","year":"2008","journal-title":"Clin J Pain"}],"container-title":["Journal of Pain and Symptom Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088539241200200X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088539241200200X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:08:31Z","timestamp":1760130511000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S088539241200200X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S088539241200200X"],"URL":"https:\/\/doi.org\/10.1016\/j.jpainsymman.2011.12.280","relation":{},"ISSN":["0885-3924"],"issn-type":[{"value":"0885-3924","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and Tolerability of Once-Daily OROS\u00ae Hydromorphone Extended-Release in Opioid-Tolerant Adults With Moderate-to-Severe Chronic Cancer and Noncancer Pain: Pooled Analysis of 11 Clinical Studies","name":"articletitle","label":"Article Title"},{"value":"Journal of Pain and Symptom Management","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpainsymman.2011.12.280","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}